Journal
EXPERT OPINION ON THERAPEUTIC TARGETS
Volume 16, Issue 11, Pages 1139-1143Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14728222.2012.714772
Keywords
brachyury; CDKN2A; chordoma; imatinib; JHC7 chordoma cell line; met; PTEN
Categories
Funding
- DePuy Spine
- Medtronic
- Neurosurgery Research and Education Foundation (NREF)
- Integra LifeSci
- AOSpine North America
Ask authors/readers for more resources
Introduction: Chordomas are malignant bone tumors arising from notochordal remnants. They most commonly occur at the sacrum, skull base, and spine. The gold standard treatment for these tumors is a combination of en-bloc resection and radiation therapy. Areas covered: Recent genomic studies have identified duplication of the gene brachyury as a major susceptibility mutation in familial chordomas. Studies on sporadic chordomas have identified several tumor markers, using microRNAs and Comparative Genome Hybridization. In this article, we highlight current advances in research on the molecular characterization of chordomas. Expert opinion: Scientific advances have allowed for the identification of numerous tumor markers involved in chordoma pathogenesis. In the future, chordoma cell lines will be produced that silence or over-express these tumor markers. As we increase our understanding of the mechanism of chordoma tumor proliferation, we can expect the development of targeted drug therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available